Random study of Entecavir and Adefovir dipivoxil in patients with chronic hepatitis B

Objective To study the short-term efficacy and safety of the treatment with entecavir (ETV) and adefovir dipivoxil (ADV) for patients with chronic hepatitis B through randomized controlled trial.Methods 99 patients were randomly divided into treatment group and control group,and the changes of HBV DNA and so on were observed.Results The negative rate of HBV DNA after 24 weeks,48 weeks and 96weeks in 2 groups had statisticaly significance (P0.05).Compared with control group,in the initial HBV DNA,in the treatment group decreased more on the 24 weeks and 48 weeks(P0.05)with one case of allergic reactions after ADV treatment;HBV DNA in 500～999 copies/mL,300～499 copies/mL and 300 copies/mL had no difference at the three intervals (P0.05);the negative rate of HBeAg (+) patients was statistically significant (P0.05);there was no HBeAg conversion in this study.Conclusion Anti-viral activity of ETV is significantly superior to ADV in early phase when chronic hepatitis B is treated and it has no significant adverse reactions.